Mumbai: Indian drug maker Dabur Pharma Ltd announced on 19 April that its founders and other shareholders have agreed to sell 73.27% in the company to Fresenius Kabi (Singapore) Pte Ltd, at Rs76.50 a share.
The Singapore firm is a unit of European healthcare firm Fresenius SE.
The Indian firm, which makes anti-cancer drugs, had earlier this year denied talks with a German drug maker for a partnership or sale. The deal with Fresenius values it about 10% higher from its market capitalization of $273 million.
Last year, the company had sold its non-oncology drugs business to local rival Alembic to focus on cancer treatment drugs.